These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 8935811)

  • 1. In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia.
    Martinot JL; Paillère-Martinot ML; Poirier MF; Dao-Castellana MH; Loc'h C; Mazière B
    Psychopharmacology (Berl); 1996 Mar; 124(1-2):154-8. PubMed ID: 8935811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia.
    Xiberas X; Martinot JL; Mallet L; Artiges E; Canal M; Loc'h C; Mazière B; Paillère-Martinot ML
    J Clin Psychopharmacol; 2001 Apr; 21(2):207-14. PubMed ID: 11270918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients.
    Bressan RA; Erlandsson K; Spencer EP; Ell PJ; Pilowsky LS
    Psychopharmacology (Berl); 2004 Sep; 175(3):367-73. PubMed ID: 14997280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. D2 receptor occupancy during high- and low-dose therapy with the atypical antipsychotic amisulpride: a 123I-iodobenzamide SPECT study.
    la Fougère C; Meisenzahl E; Schmitt G; Stauss J; Frodl T; Tatsch K; Hahn K; Möller HJ; Dresel S
    J Nucl Med; 2005 Jun; 46(6):1028-33. PubMed ID: 15937316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Striatal D2/D3 receptor occupancy, clinical response and side effects with amisulpride: an iodine-123-iodobenzamide SPET study.
    Meisenzahl EM; Schmitt G; Gründer G; Dresel S; Frodl T; la Fougère C; Scheuerecker J; Schwarz M; Boerner R; Stauss J; Hahn K; Möller HJ
    Pharmacopsychiatry; 2008 Sep; 41(5):169-75. PubMed ID: 18763218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients.
    Bressan RA; Erlandsson K; Jones HM; Mulligan R; Flanagan RJ; Ell PJ; Pilowsky LS
    Am J Psychiatry; 2003 Aug; 160(8):1413-20. PubMed ID: 12900302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia.
    Vernaleken I; Siessmeier T; Buchholz HG; Härtter S; Hiemke C; Stoeter P; Rösch F; Bartenstein P; Gründer G
    Int J Neuropsychopharmacol; 2004 Dec; 7(4):421-30. PubMed ID: 15683553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease.
    Reeves S; McLachlan E; Bertrand J; D'Antonio F; Brownings S; Nair A; Greaves S; Smith A; Taylor D; Dunn J; Marsden P; Kessler R; Howard R
    Brain; 2017 Apr; 140(4):1117-1127. PubMed ID: 28334978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.
    Nyberg S; Eriksson B; Oxenstierna G; Halldin C; Farde L
    Am J Psychiatry; 1999 Jun; 156(6):869-75. PubMed ID: 10360125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frontal fasciculi and psychotic symptoms in antipsychotic-naive patients with schizophrenia before and after 6 weeks of selective dopamine D2/3 receptor blockade.
    Ebdrup BH; Raghava JM; Nielsen MØ; Rostrup E; Glenthøj B
    J Psychiatry Neurosci; 2016 Mar; 41(2):133-41. PubMed ID: 26599135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.
    Schoemaker H; Claustre Y; Fage D; Rouquier L; Chergui K; Curet O; Oblin A; Gonon F; Carter C; Benavides J; Scatton B
    J Pharmacol Exp Ther; 1997 Jan; 280(1):83-97. PubMed ID: 8996185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Towards a therapeutic window of D2/3 occupancy for treatment of psychosis in Alzheimer's disease, with [18F]fallypride positron emission tomography.
    Clark-Papasavas C; Dunn JT; Greaves S; Mogg A; Gomes R; Brownings S; Liu K; Nwosu B; Marsden P; Joemon J; Cleij M; Kessler R; Howard R; Reeves S
    Int J Geriatr Psychiatry; 2014 Oct; 29(10):1001-9. PubMed ID: 24578318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of amisulpride, an atypical antipsychotic which blocks preferentially presynaptic dopamine autoreceptors, on integrated functional cerebral activity in the rat.
    Cudennec A; Fage D; Bénavidès J; Scatton B
    Brain Res; 1997 Sep; 768(1-2):257-65. PubMed ID: 9369323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antipsychotic sultopride is overdosed--a PET study of drug-induced receptor occupancy in comparison with sulpiride.
    Takano A; Suhara T; Yasuno F; Suzuki K; Takahashi H; Morimoto T; Lee YJ; Kusuhara H; Sugiyama Y; Okubo Y
    Int J Neuropsychopharmacol; 2006 Oct; 9(5):539-45. PubMed ID: 16288681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating dopamine D₂ receptor occupancy for doses of 8 antipsychotics: a meta-analysis.
    Lako IM; van den Heuvel ER; Knegtering H; Bruggeman R; Taxis K
    J Clin Psychopharmacol; 2013 Oct; 33(5):675-81. PubMed ID: 23948784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy.
    Kapur S; Zipursky R; Jones C; Shammi CS; Remington G; Seeman P
    Arch Gen Psychiatry; 2000 Jun; 57(6):553-9. PubMed ID: 10839333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride.
    Yokoi F; Gründer G; Biziere K; Stephane M; Dogan AS; Dannals RF; Ravert H; Suri A; Bramer S; Wong DF
    Neuropsychopharmacology; 2002 Aug; 27(2):248-59. PubMed ID: 12093598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Striatal D(2/3) Binding Potential Values in Drug-Naïve First-Episode Schizophrenia Patients Correlate With Treatment Outcome.
    Wulff S; Pinborg LH; Svarer C; Jensen LT; Nielsen MØ; Allerup P; Bak N; Rasmussen H; Frandsen E; Rostrup E; Glenthøj BY
    Schizophr Bull; 2015 Sep; 41(5):1143-52. PubMed ID: 25698711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone.
    Mamo D; Kapur S; Shammi CM; Papatheodorou G; Mann S; Therrien F; Remington G
    Am J Psychiatry; 2004 May; 161(5):818-25. PubMed ID: 15121646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study.
    Bigliani V; Mulligan RS; Acton PD; Ohlsen RI; Pike VW; Ell PJ; Gacinovic S; Kerwin RW; Pilowsky LS
    Psychopharmacology (Berl); 2000 Jun; 150(2):132-40. PubMed ID: 10907666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.